• March 24, 2002

  • March 22, 2002

  • March 20, 2002

    If It Were Easy. . .

    As I mentioned yesterday, Viropharma’s compound Picovir (pleconaril) was turned down unanimously by an FDA panel. This could be the end for an interesting compound that’s been kicking around for many years, going back to the days (1990 or so) when Sterling-Winthrop still existed as a drug company. Kodak took over Sterling in 1988, looki… Read More
  • March 19, 2002

    Mirror Stars

    No longer can I say that the topic of allergenic extraterrestrial life hasn’t been taken on in science fiction. Patrick Neilsen Hayden of Electrolite, who is certainly in a professional position to know, passes on the word that the 1999 novel BIOS (by Robert Charles Wilson, reviewed) includes this very idea. On a related topic… Read More
  • March 10, 2002

    Separation Anxiety

    Sepracor‘s really taken a pounding after an FDA “non-approvable” letter for their antihistamine compound. But they haven’t been a quiet drug stock to be in, and it isn’t a quiet company. They certainly don’t have a quiet business plan, either. As readers who are in the business are well aware, Sepracor doesn̵… Read More
  • February 27, 2002

    More Imclone, More Food for Thought

    As you’ve no doubt heard, Imclone issued a press release this morning about their FDA meeting. It seems that if they can come up with more clinical data from Merck KGaA’s European trials, along with clarifying some of their own numbers, then the FDA has agreed to look at a resubmission. Bristol Meyers-Squibb has been… Read More
  • Who Dares, Wins?

    I’d like to take the time to sympathize with Elan Pharmaceuticals over what’s happened to their Alzheimer’s trial. They had the initiative (and the nerve) to pick up and run with an unusual discovery: that a protein that precipitates in the brains of Alzheimer’s patients, beta-amyloid, can be attacked by an immune response.… Read More
  • February 26, 2002

    A Certain Tension in the Air

    Well, today is Imclone day at the FDA (see Jan 31 and Feb. 6 postings.) All parties will be meeting to decide what the path forward is: reworking the existing data, supplementing it with whatever else the companies can dredge up, or new clinical trials. Analysts have raised the possibility of using some clinical data… Read More
  • New Drugs for HIV

    Megan McArdle points out the recent news (which has shown up in Tuesday’s NY Times and other outlets as well) about new HIV treatments with possibly fewer side effects. She asks if the same technique can be applied to other diseases, and I thought for the benefit of the non-pharma audience that I’d go into… Read More
  • February 25, 2002

Page 527 of 528« First...102030...524525526527528